Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.…
Appili Therapeutics Announces Transfer to NEX
Appili Therapeutics (TSE: APLI) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 0.0050 CAD on 19 November 2026, down 80.0% over 52 weeks. Its 52-week range is 0.0050 CAD to 0.0300 CAD, and it trades at the bottom of that range.
Its market capitalisation is 661.83K CAD.
Appili Therapeutics reports return on equity of 24.5%.
Its debt exceeds its cash by 13.19M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 February 2027.